317 related articles for article (PubMed ID: 29409706)
21. Pharmacological targeting of RAS: Recent success with direct inhibitors.
O'Bryan JP
Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
[TBL] [Abstract][Full Text] [Related]
22. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
23. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.
Klochkov SG; Neganova ME; Yarla NS; Parvathaneni M; Sharma B; Tarasov VV; Barreto G; Bachurin SO; Ashraf GM; Aliev G
Semin Cancer Biol; 2019 Jun; 56():128-134. PubMed ID: 29100957
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
25. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
Aguilar BJ; Zhou H; Lu Q
Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
[TBL] [Abstract][Full Text] [Related]
26. New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics.
Esposito D; Stephen AG; Turbyville TJ; Holderfield M
Semin Cancer Biol; 2019 Feb; 54():174-182. PubMed ID: 29432816
[TBL] [Abstract][Full Text] [Related]
27. Past, Present, and Future of Targeting Ras for Cancer Therapies.
Tan Z; Zhang S
Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs.
Quah SY; Tan MS; Teh YH; Stanslas J
Pharmacol Ther; 2016 Jun; 162():35-57. PubMed ID: 27016467
[TBL] [Abstract][Full Text] [Related]
29. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
30. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
32. Sugar-based inhibitors of Ras activation: biological activity and identification of Ras-inhibitor binding interface.
Di Domizio A; Peri F
Enzymes; 2013; 33 Pt A():95-116. PubMed ID: 25033802
[TBL] [Abstract][Full Text] [Related]
33. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
[TBL] [Abstract][Full Text] [Related]
34. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.
Chen M; Peters A; Huang T; Nan X
Mini Rev Med Chem; 2016; 16(5):391-403. PubMed ID: 26423697
[TBL] [Abstract][Full Text] [Related]
35. How to make an undruggable enzyme druggable: lessons from ras proteins.
Sayyed-Ahmad A; Gorfe AA
Adv Protein Chem Struct Biol; 2020; 122():181-202. PubMed ID: 32951811
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of chronically active ras: potential for treatment of human malignancies.
Blum R; Cox AD; Kloog Y
Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):31-47. PubMed ID: 18289122
[TBL] [Abstract][Full Text] [Related]
37. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.
Shima F; Yoshikawa Y; Ye M; Araki M; Matsumoto S; Liao J; Hu L; Sugimoto T; Ijiri Y; Takeda A; Nishiyama Y; Sato C; Muraoka S; Tamura A; Osoda T; Tsuda K; Miyakawa T; Fukunishi H; Shimada J; Kumasaka T; Yamamoto M; Kataoka T
Proc Natl Acad Sci U S A; 2013 May; 110(20):8182-7. PubMed ID: 23630290
[TBL] [Abstract][Full Text] [Related]
38. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
Marcus K; Mattos C
Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
[TBL] [Abstract][Full Text] [Related]
39. Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction.
Shima F; Yoshikawa Y; Matsumoto S; Kataoka T
Enzymes; 2013; 34 Pt. B():1-23. PubMed ID: 25034098
[TBL] [Abstract][Full Text] [Related]
40. Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction.
Chen D; Chen Y; Lian F; Chen L; Li Y; Cao D; Wang X; Chen L; Li J; Meng T; Huang M; Geng M; Shen J; Zhang N; Xiong B
Eur J Med Chem; 2019 Feb; 163():597-609. PubMed ID: 30562696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
